Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

Michel Dominique Ferrari; Uwe Reuter; Peter J Goadsby; Gabriel Paiva da Silva Lima; Subhayan Mondal; Shihua Wen; Nadia Tenenbaum; Shaloo Pandhi; Michel Lanteri-Minet; Tracy Stites

doi:10.1136/jnnp-2021-327480

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF

PDF +
Supplementary
Material

Migraine

Original research

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Ferrari MD, Reuter U, Goadsby PJ, et al

Two-year efficacy and safety of erenumab in participants with episodic migraine and 2–4 prior preventive treatment failures: results from the LIBERTY study

Journal of Neurology, Neurosurgery & Psychiatry 2022;93:254-262.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password